Pfizer and BioNTech have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the authorization of their monovalent COVID-19 vaccine, adapted to the Omicron JN.1 variant from the age of 6 months.

The European Commission will examine this recommendation and is expected to make a final decision shortly.

Pfizer and BioNTech announce that they have already manufactured this vaccine in anticipation of increased demand for the fall and winter seasons.


Copyright (c) 2024 CercleFinance.com. All rights reserved.